Acoustofluidic sonoporation for gene delivery to human hematopoietic stem and progenitor cells
- aCalifornia NanoSystems Institute, University of California, Los Angeles, CA 90095;
- bDepartment of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095;
- cDepartment of Mechanical Engineering and Material Science, Duke University, Durham, NC 27707;
- dDepartment of Aerospace Engineering, Mississippi State University, Starkville, MS 39762;
- eDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095;
- fChildren’s Discovery and Innovation Institute, University of California, Los Angeles, CA 90095;
- gDepartment of Medicine and the Molecular Biology Institute, University of California, Los Angeles, CA 90095;
- hDepartment of Human Genetics and the Molecular Biology Institute, University of California, Los Angeles, CA 90095;
- iDepartment of Materials Science and Engineering, University of California, Los Angeles, CA 90095;
- jEli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095
See allHide authors and affiliations
Edited by Jennifer A. Doudna, University of California, Berkeley, CA, and approved March 30, 2020 (received for review October 3, 2019)

Significance
Commercial strategies to deliver biomolecular cargo ex vivo (e.g., electroporation, lipofection) to clinically relevant cell lines are limited by toxicity, cost, and throughput. These technical limitations have inhibited development of these technologies into streamlined clinical platforms for manufacturing gene-modified stem cells and cancer immunotherapies. Here, we demonstrate an acoustofluidic platform capable of delivering plasmids with high throughput to human T lymphocytes, peripheral blood mononuclear cells, and CD34+ hematopoietic stem and progenitor cells. Acoustofluidic-treated cells showed evidence of cytosolic DNA delivery, endocytic DNA aggregation, and nuclear membrane rupture. Collectively, these observations demonstrate the utility of this method as a research tool for gene editing applications and mechanistic studies of plasma membrane and nuclear membrane repair.
Abstract
Advances in gene editing are leading to new medical interventions where patients’ own cells are used for stem cell therapies and immunotherapies. One of the key limitations to translating these treatments to the clinic is the need for scalable technologies for engineering cells efficiently and safely. Toward this goal, microfluidic strategies to induce membrane pores and permeability have emerged as promising techniques to deliver biomolecular cargo into cells. As these technologies continue to mature, there is a need to achieve efficient, safe, nontoxic, fast, and economical processing of clinically relevant cell types. We demonstrate an acoustofluidic sonoporation method to deliver plasmids to immortalized and primary human cell types, based on pore formation and permeabilization of cell membranes with acoustic waves. This acoustofluidic-mediated approach achieves fast and efficient intracellular delivery of an enhanced green fluorescent protein-expressing plasmid to cells at a scalable throughput of 200,000 cells/min in a single channel. Analyses of intracellular delivery and nuclear membrane rupture revealed mechanisms underlying acoustofluidic delivery and successful gene expression. Our studies show that acoustofluidic technologies are promising platforms for gene delivery and a useful tool for investigating membrane repair.
Footnotes
- ↵1To whom correspondence may be addressed. Email: psw{at}cnsi.ucla.edu or sjjonas{at}mednet.ucla.edu.
Author contributions: J.N.B., S.G.Y., A.Z.S., S.D.O., T.J.H., P.S.W., and S.J.J. designed research; J.N.B., L.K.H., Z.T., A.M.M., T.-T.C., N.Y.C., T.D.Y., N.W., J.H.P., and J.T. performed research; J.N.B., P.S.W., and S.J.J. analyzed data; and J.N.B., L.K.H., Z.T., Y.G., N.Y.C., T.D.Y., N.W., J.H.P., L.S., N.C., J.T., S.G.Y., A.Z.S., S.D.O., T.J.H., P.S.W., and S.J.J. wrote the paper.
Competing interest statement: P.S.W., S.J.J., A.Z.S., and J.N.B. are inventors on US and international patent applications filed by the Regents of the University of California relating to the acoustofluidic platform.
This article is a PNAS Direct Submission.
This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1917125117/-/DCSupplemental.
Published under the PNAS license.
Citation Manager Formats
Article Classifications
- Biological Sciences
- Medical Sciences
- Physical Sciences
- Engineering